NASDAQ Biotechnology Companies By Enterprise Value

LargestBiggest EarnersMost ProfitableMost LiquidHighly LeveragedTop DividendsCapital-HeavyHighest ValuationLargest Workforce
Current Valuation
Return On Equity
Return On Asset
Profit Margin
Operating Margin
Current Valuation
Shares Outstanding
Shares Owned By Insiders
Shares Owned By Institutions
Number Of Shares Shorted
Price To Earning
Price To Book
Price To Sales
Revenue
Gross Profit
EBITDA
Net Income
Cash And Equivalents
Cash Per Share
Total Debt
Debt To Equity
Current Ratio
Book Value Per Share
Cash Flow From Operations
Short Ratio
Earnings Per Share
Price To Earnings To Growth
Target Price
Number Of Employees
Beta
Market Capitalization
Total Asset
Retained Earnings
Working Capital
Current Asset
Current Liabilities
Current ValuationEfficiencyMarket RiskExp Return
1AZN AstraZeneca PLC ADR
235.48 B
(0.24)
 1.50 
(0.36)
2AMGN Amgen Inc
203.44 B
(0.13)
 1.68 
(0.22)
3SNY Sanofi ADR
139.83 B
(0.22)
 1.17 
(0.26)
4GILD Gilead Sciences
133.59 B
 0.18 
 1.41 
 0.26 
5VRTX Vertex Pharmaceuticals
115.74 B
(0.01)
 1.67 
(0.01)
6REGN Regeneron Pharmaceuticals
75.35 B
(0.39)
 1.72 
(0.68)
7ARGX argenx NV ADR
34.24 B
 0.15 
 1.99 
 0.30 
8ALNY Alnylam Pharmaceuticals
31.16 B
 0.01 
 2.15 
 0.02 
9VTRS Viatris
29.6 B
 0.08 
 2.27 
 0.17 
10BIIB Biogen Inc
28.36 B
(0.28)
 1.32 
(0.37)
11ILMN Illumina
24.6 B
 0.08 
 2.28 
 0.18 
12BGNE BeiGene
22.24 B
 0.09 
 2.62 
 0.24 
13RPRX Royalty Pharma Plc
17.69 B
(0.11)
 0.99 
(0.11)
14GRFS Grifols SA ADR
14.52 B
(0.12)
 3.30 
(0.40)
15UTHR United Therapeutics
13.61 B
 0.05 
 1.69 
 0.09 
16SMMT Summit Therapeutics PLC
13.16 B
 0.10 
 9.60 
 0.98 
17INSM Insmed Inc
12.98 B
 0.03 
 2.47 
 0.07 
18SRPT Sarepta Therapeutics
12.94 B
 0.01 
 2.69 
 0.01 
19INCY Incyte
12.63 B
 0.09 
 2.50 
 0.21 
20BMRN Biomarin Pharmaceutical
12.26 B
(0.18)
 2.58 
(0.47)
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents. Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY